Bristol-Myers Squibb Co., of New York, and Abbvie Inc., of Chicago, announced updated efficacy and safety data from a small, randomized Phase II, open-label study in patients with previously treated multiple myeloma that evaluated two doses of the investigational monoclonal antibody elotuzumab (10 mg/kg and 20 mg/kg) in combination with lenalidomide and low-dose dexamethasone

Bristol-Myers Squibb Co. (BMS), of New York, and Simcere Pharmaceutical Group, of Nanjing, China, expanded their strategic relationship formed in 2010

Myers Squibb Co. (New York) Nivolumab An anti-PD-1 Inoperable Stage III and Stage IV melanoma In combination with the anti-CTLA-4 ipilimumab suggested it led to an objective response rate of 53% in the largest group of patients in the Phase I study 5/16/13 Bristol-Myers Squibb Co. (New York) Sustiva Efavirenz HIV FDA approved an sNDA 5/6/13 Bristol-Myers Squibb Co. (New York) Metreleptin Analogue of leptin Metabolic disorders Results from a 12-month subgroup analysis showed it led to mean

Bristol-Myers Squibb Co., of New York, reported year two data from the AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis Subjects With Background Methotrexate) trial of 646 patients comparing the safety and efficacy of the subcutaneous formulation of abatacept (Orencia) vs

San Diego-based Ambrx Inc.'s site-specific ADC platform drew Bristol-Myers Squibb Co., of New York, for a third deal in May

As first shown by very long-term responses to Yervoy (ipilimumab, Bristol-Myers Squibb Co.), immunotherapy offers metastatic cancer patients the best shot at what they really want: not a three-month or six-month increase in survival, but a chance to bore their grandchildren with war stories about their illnesses and how they survived

San Diego-based Ambrx Inc.'s site-specific ADC platform drew Bristol-Myers Squibb Co., of New York, for a third deal in May

Bristol-Myers Squibb Co., of Princeton, N.J., and AstraZeneca plc, of London, said the FDA accepted for review and granted priority designation for the biologics license application for metreleptin in metabolic disorders associated with inherited or acquired lipodsytrophy

Suzanne Topalian is the principal investigator on studies of Bristol-Myers Squibb Co.'s immunotherapy nivolumab

However, a first pass at key overall survival (OS) findings suggested the compound may still be in the mix for melanoma, though perhaps with a lower anticipated market opportunity than currently marketed Yervoy (ipilimumab, Bristol-Myers Squibb Co.) and highly anticipated PD-1 therapies

AbbVie Inc., of Chicago, reported results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and relapsed/refractory non-Hodgkin's lymphoma (NHL). The Phase I, open-label, multicenter, international trial was designed to assess the safety, determine the maximum tolerated dose and recommended Phase II dose, and evaluate the pharmacokinetics of ABT-199 in

While last year's American Society of Clinical Oncology (ASCO) meeting ended on cautiously encouraging advances in the cancer immunotherapy space, this year's meeting has put immunotherapy front and center, thanks in part to much-awaited data on and anti-PDL-1 and anti-PD-1 drugs from Roche AG and Bristol-Myers Squibb Co., respectively. (See BioWorld Today, June 6, 2012.) Those drugs, both check point inhibitors, generated significant buzz going into the ASCO meeting in Chicago

Prometheus Laboratories Inc., of San Diego, said PROCLIVITY02, a study comparing the sequence of Proleukin (high dose interleukin-2), followed by Yervoy (ipilimumab, Bristol-Myers Squibb Co.) to the converse order, as therapy in patients with metastatic melanoma, has investigational review board approval and anticipates enrolling patients this summer

Portola has partnered with Bristol-Myers Squibb Co

New York-based Bristol-Myers Squibb Co.'s CTLA-4 blocker Yervoy (ipilimumab) won FDA clearance in April 2011 , and another drug given the nod that summer was the kinase inhibitor for patients with the BRAF V600E mutation, Zelboraf (vemurafenib, Daiichi Sankyo Co. Ltd. and Roche AG). (See BioWorld Today, April 4, 2011, and Aug, 18, 2011.) It was those two approvals against which analysts weighed the chances of Thousand Oaks, Calif.-based Amgen Inc.'s talimogene laherparepvec, or T-VEC, brought

Inc. (Whitehouse Station, N.J.) Bristol-Myers Squibb Co. (New York) ND Nonexclusive deal to conduct a Phase II trial of a once-daily oral combination regimen consisting of BMS' NS5A replication complex inhibitor daclatasvir and Merck's NS3/4A protease inhibitor MK-5172 to treat chronic hepatitis C virus Merck will conduct the trial 4/23/13 Merck KGgA (Darmstadt, Germany) Pfizer Inc. (New York) ND Extended collaboration signed in 2002 by Merck's subsidiary EMD Serono Inc

Merck gains worldwide commercialization rights and will pay royalties to Abide 5/3/13 Adaptive Biotechnologies (Seattle) Bristol-Myers Squibb Co. (New York) ND Collaboration for the discovery of immunological biomarkers in oncology Adaptive will use its immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response 5/10/13 Afraxis Inc. (San Diego) Institut de Recherches Servier (Paris) ND Nonexclusive collaboration to use the enhanced spine platform

Bristol-Myers Squibb Co., of New York, said it has notified the New York Stock Exchange (NYSE) of its intention to voluntarily delist its $2 convertible preferred stock from the NYSE, a decision driven by the low number of shares outstanding, low daily trading volume, listing fees and compliance administration costs